These results, together with ours, suggest that therapeutic strategies aimed at blocking NF-κB activity should prove beneficial for KRAS-induced lung cancer therapy, especially in patients with simultaneous loss or mutation of p53. The gene discussed is TP53; the disease is lung carcinoma.